Psychopharmacology

, Volume 187, Issue 1, pp 68–72

Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder

Original Investigation

Abstract

Objectives

To determine whether variation in the serotonin transporter gene promoter (5HTTLPR) influences the efficacy of selective serotonin reuptake inhibitors (SSRIs) in generalized social anxiety disorder (GSAD).

Methods

Consecutive series of N=32 patients with DSM-IV GSAD for whom DNA and standardized outcome data from a 12-week SSRI trial were available. After ensuring that neither clinical response [clinical global impression of change scale (CGI-C)] nor 5HTTLPR genotype was confounded by ethnicity or sex, we determined whether the number of copies (0, 1, or 2) of hi-risk alleles using either the diallelic L–S system or the triallelic La–Lg–S system, predicted response and change in Liebowitz social anxiety scale (LSAS) and brief social phobia scale (BSPS) scores during SSRI treatment.

Results

Twenty-one patients (66%) were responders to SSRI (i.e., CGI-C much or very much improved). A trend was seen for a linear association between 5HTTLPR genotype and likelihood of response to SSRI: diallelic classification L/L 7/8 (88%), L/S 12/18 (67%), S/S 2/6 (33%), p=0.051; triallelic classification L′/L′ 4/5 (80%), L′/S′ 14/19 (74%), S′/S′ 3/8 (38%), p=0.093. Reduction in LSAS (and BSPS) scores during SSRI treatment was significantly (p<0.02) associated with 5HTTLPR genotype using either the diallelic or triallelic classification.

Conclusions

Variation in a functional polymorphism known to influence serotonin reuptake is associated with SSRI response in patients with GSAD. Independent replication in larger samples is required before the predictive utility of this information can be confirmed and generalized to clinical settings.

Keywords

Selective serotonin reuptake inhibitor (SSRI) Social anxiety disorder (SAD) Pharmacotherapy Genetics Polymorphism Pharmacogenomics 

References

  1. Argyropoulos SV, Hood SD, Adrover M, Bell CJ, Rich AS, Nash JR, Rich NC, Witchel HJ, Nutt DJ (2004) Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry 56:503–509CrossRefPubMedGoogle Scholar
  2. Bauman MD, Amaral DG (2005) The distribution of serotonergic fibers in the macaque monkey amygdala: an immunohistochemical study using antisera to 5-hydroxytryptamine. Neuroscience 136:193–203CrossRefPubMedGoogle Scholar
  3. Charney DS (2004) Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. Am J Psychiatry 161:1–2CrossRefPubMedGoogle Scholar
  4. Davidson JRT, Miner CM, DeVeaugh-Geiss J, Tupler LA, Colket JT, Potts NL (1997) The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 27:161–166CrossRefPubMedGoogle Scholar
  5. Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Langstrom B, Oreland L, Fredrikson M (2004) Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 362:189–192CrossRefPubMedGoogle Scholar
  6. Gelernter J, Kranzler H, Cubells JF (1997) Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 101:243–246CrossRefPubMedGoogle Scholar
  7. Guy W (1976) ECDEU Assessment manual for psychopharmacology, Revised. Rockville, MD, National Institute for Mental HealthGoogle Scholar
  8. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR (2005) A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62:146–152CrossRefPubMedGoogle Scholar
  9. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR (1999) Psychometric properties of the Liebowitz social anxiety scale. Psychol Med 29:199–212CrossRefPubMedGoogle Scholar
  10. Hu X, Oroszi G, Chun J, Smith TL, Goldman D, Schuckit MA (2005) An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res 29:8–16CrossRefPubMedGoogle Scholar
  11. Kessler RC, Stein MB, Berglund PA (1998) Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 155:613–619PubMedGoogle Scholar
  12. Kessler RC, Stang P, Wittchen H-U, Stein MB, Walters EE (1999) Lifetime comorbidities between social phobia and mood disorders in the U.S. national comorbidity survey. Psychol Med 29:555–567CrossRefPubMedGoogle Scholar
  13. Kessler RC, Berglund P, Demler O, Jin R, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593–602CrossRefPubMedGoogle Scholar
  14. Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K (2004) Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 161:2215–2221CrossRefPubMedGoogle Scholar
  15. Lesch K-P, Bengel D, Heils A, Sabol SA, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531CrossRefPubMedGoogle Scholar
  16. Liu K, Muse SV (2005) PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 21:2128–2129 (Free program distributed by the author over the internet from http://www.powermarker.net)Google Scholar
  17. Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780–796CrossRefPubMedGoogle Scholar
  18. Monteleone P, Santonastaso P, Tortorella A, Favaro A, Fabrazzo M, Castaldo E, Caregaro L, Fuschino A, Maj M (2005) Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. Mol Psychiatry 10:716–718CrossRefPubMedGoogle Scholar
  19. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ (2006) Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 163:48–51CrossRefPubMedGoogle Scholar
  20. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L (2005) Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 30:2230–2235CrossRefPubMedGoogle Scholar
  21. Schneier FR (2003) Social anxiety disorder. BMJ 327:515–516CrossRefPubMedGoogle Scholar
  22. Stein MB, Gorman JM (2001) Unmasking social anxiety disorder. J Psychiatry Neurosci 26:185–189PubMedGoogle Scholar
  23. Stein MB, Kean Y (2000) Disability and quality of life in social phobia. Am J Psychiatry 157:1606–1613CrossRefPubMedGoogle Scholar
  24. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B (2002a) Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 63:152–155PubMedGoogle Scholar
  25. Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG (2002b) Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 59:1027–1034CrossRefPubMedGoogle Scholar
  26. Stein DJ, Ipser JC, Balkom AJ (2004) Pharmacotherapy for social phobia. Cochrane Database Syst Rev CD001206Google Scholar
  27. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280–288CrossRefGoogle Scholar
  28. Van Ameringen M, Oakman J, Mancini C, Pipe B, Chung H (2004) Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol 24:42–48CrossRefPubMedGoogle Scholar
  29. Van Ameringen M, Mancini C, Patterson B, Bennett M (2005) An evaluation of paroxetine in generalised social anxiety disorder. Expert Opin Pharmacother 6:819–830CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Murray B. Stein
    • 1
  • Soraya Seedat
    • 2
  • Joel Gelernter
    • 3
  1. 1.Departments of Psychiatry and Family & Preventive MedicineUniversity of CaliforniaSan DiegoUSA
  2. 2.Department of PsychiatryStellenbosch UniversityStellenboschSouth Africa
  3. 3.Department of PsychiatryYale University School of MedicineNew HavenUSA

Personalised recommendations